New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
June 29, 2018 - Dermira announced the FDA approval of Qbrexza (glycopyrronium) for topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older.
Download PDF
Return to publications
